Medicamen Biotech Ltd vs Ngl Fine Chem Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Medicamen Biotech Ltd is ₹ 253.3 as of 30 Apr 15:30 . The P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 yearsThe P/E Ratio of NGL Fine Chem Ltd changed from 16.7 on March 2021 to 32.6 on March 2025 . This represents a CAGR of 14.31% over 5 years The Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 yearsThe Market Cap of NGL Fine Chem Ltd changed from ₹ 947.42 crore on March 2021 to ₹ 688.7 crore on March 2025 . This represents a CAGR of -6.18% over 5 years The revenue of Medicamen Biotech Ltd for the Dec '25 is ₹ 47.44 crore as compare to the Sep '25 revenue of ₹ 47.54 crore. This represent the decline of -0.21% The revenue of NGL Fine Chem Ltd for the Dec '25 is ₹ 132.12 crore as compare to the Sep '25 revenue of ₹ 122.31 crore. This represent the growth of 8.02% The ebitda of Medicamen Biotech Ltd for the Dec '25 is ₹ 4.91 crore as compare to the Sep '25 ebitda of ₹ 5.53 crore. This represent the decline of -11.21% The ebitda of NGL Fine Chem Ltd for the Dec '25 is ₹ 26.93 crore as compare to the Sep '25 ebitda of ₹ 19.21 crore. This represent the growth of 40.19% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 1.63 crore over 7 quarters. This represents a CAGR of 50.19% The net profit of NGL Fine Chem Ltd changed from ₹ 9.22 crore to ₹ 15.69 crore over 7 quarters. This represents a CAGR of 35.50% The Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 yearsThe Dividend Payout of NGL Fine Chem Ltd changed from 1.95 % on March 2021 to 5.97 % on March 2025 . This represents a CAGR of 25.08% over 5 years .

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

About NGL Fine Chem Ltd

NGL Fine-Chem Limited was incorporated on December 18, 1981 as a Private Limited Company in the State of Maharashtra.
The Company became a Public Limited Company.
The Company has got its registered office and factory at New Bombay.
It was promoted by Mr. A.G.Lawande, Mr.R. J. Nachane joined Mr.A.G.Lawande for actively participating in the Management of the Company in 1989.
The Company is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health.

FAQs for the comparison of Medicamen Biotech Ltd and NGL Fine Chem Ltd

Which company has a larger market capitalization, Medicamen Biotech Ltd or NGL Fine Chem Ltd?

Market cap of Medicamen Biotech Ltd is 343 Cr while Market cap of NGL Fine Chem Ltd is 1,387 Cr

What are the key factors driving the stock performance of Medicamen Biotech Ltd and NGL Fine Chem Ltd?

The stock performance of Medicamen Biotech Ltd and NGL Fine Chem Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Medicamen Biotech Ltd and NGL Fine Chem Ltd?

As of May 4, 2026, the Medicamen Biotech Ltd stock price is INR ₹253.3. On the other hand, NGL Fine Chem Ltd stock price is INR ₹2244.7.

How do dividend payouts of Medicamen Biotech Ltd and NGL Fine Chem Ltd compare?

To compare the dividend payouts of Medicamen Biotech Ltd and NGL Fine Chem Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.